Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics

Andrea Galbiati, Paulina Dorten, Ettore Gilardoni, Florian Gierse, Matilde Bocci, Aureliano Zana, Jacqueline Mock, Michael Claesener, Juela Cufe, Florian Büther, Klaus Schäfers, Sven Hermann, Michael Schäfers, Dario Neri, Samuele Cazzamalli and Philipp Backhaus
Journal of Nuclear Medicine December 2023, 64 (12) 1934-1940; DOI: https://doi.org/10.2967/jnumed.123.266007
Andrea Galbiati
1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulina Dorten
2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ettore Gilardoni
1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Gierse
2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matilde Bocci
1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aureliano Zana
1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Mock
1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Claesener
3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juela Cufe
2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian Büther
3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Schäfers
2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven Hermann
2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Schäfers
2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;
4West German Cancer Centre, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dario Neri
5Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and
6Philogen S.p.A., Siena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuele Cazzamalli
1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Backhaus
2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;
4West German Cancer Centre, Münster, Germany;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 12 1934-1940
DOI 
https://doi.org/10.2967/jnumed.123.266007
PubMed 
37734838

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 8, 2023
  • Revision received August 18, 2023
  • Published online December 1, 2023.

Article Versions

  • previous version (September 21, 2023 - 06:41).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Andrea Galbiati*,1,
  2. Paulina Dorten*,2,
  3. Ettore Gilardoni1,
  4. Florian Gierse2,
  5. Matilde Bocci1,
  6. Aureliano Zana1,
  7. Jacqueline Mock1,
  8. Michael Claesener3,
  9. Juela Cufe2,3,
  10. Florian Büther3,
  11. Klaus Schäfers2,
  12. Sven Hermann2,
  13. Michael Schäfers2,3,4,
  14. Dario Neri5,6,
  15. Samuele Cazzamalli1 and
  16. Philipp Backhaus2,3,4
  1. 1Research and Development Department, Philochem AG, Otelfingen, Switzerland;
  2. 2European Institute for Molecular Imaging, University of Münster, Münster, Germany;
  3. 3Department of Nuclear Medicine, University Hospital Münster, Münster, Germany;
  4. 4West German Cancer Centre, Münster, Germany;
  5. 5Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology, Zurich, Switzerland; and
  6. 6Philogen S.p.A., Siena, Italy
  1. For correspondence or reprints, contact Samuele Cazzamalli (samuele.cazzamalli{at}philochem.ch) or Philipp Backhaus (philipp.backhaus{at}ukmuenster.de).
View Full Text

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • 6 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention
    Andrea Galbiati, Matilde Bocci, Silvia Gervasoni, Eleonora Prodi, Giuliano Malloci, Dario Neri, Samuele Cazzamalli
    Journal of Medicinal Chemistry 2024 67 15
  • Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody–Drug Conjugate Targeting Fibroblast Activation Protein
    Joseph P. Gallant, Hallie M. Hintz, Gihan S. Gunaratne, Matthew T. Breneman, Emma E. Recchia, Jayden L. West, Kendahl L. Ott, Erika Heninger, Abigail E. Jackson, Natalie Y. Luo, Zachary T. Rosenkrans, Reinier Hernandez, Shuang G. Zhao, Joshua M. Lang, Labros Meimetis, David Kosoff, Aaron M. LeBeau
    Cancer Research Communications 2024 4 6
  • Preclinical Evaluation of177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors
    Andrea Galbiati, Matilde Bocci, Domenico Ravazza, Jacqueline Mock, Ettore Gilardoni, Dario Neri, Samuele Cazzamalli
    Journal of Nuclear Medicine 2024 65 10
  • Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy
    Eleonora Prodi, Dario Neri, Roberto De Luca
    OncoTargets and Therapy 2024 Volume 17
  • Effect of molar dose on the in vivo tissue biodistribution profile of FAP-targeted radioligand therapeutics
    Andrea Galbiati, Matilde Bocci, Dario Neri, Samuele Cazzamalli
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 4
  • Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto™
    Tony Georgiev, Lucrezia Principi, Andrea Galbiati, Ettore Gilardoni, Dario Neri, Samuele Cazzamalli
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 8

Article usage

Article usage: September 2023 to April 2025

AbstractFullPdf
Sep 2023169010365
Oct 20236899535
Nov 202314323863
Dec 2023460295132
Jan 202418524178
Feb 20247421146
Mar 20245118373
Apr 20245819273
May 20241616935
Jun 2024409643
Jul 20244018757
Aug 20242716448
Sep 2024328348
Oct 20242810156
Nov 2024379081
Dec 2024178637
Jan 2025216148
Feb 20252715345
Mar 20252610146
Apr 2025239579
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (12)
Journal of Nuclear Medicine
Vol. 64, Issue 12
December 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
Andrea Galbiati, Paulina Dorten, Ettore Gilardoni, Florian Gierse, Matilde Bocci, Aureliano Zana, Jacqueline Mock, Michael Claesener, Juela Cufe, Florian Büther, Klaus Schäfers, Sven Hermann, Michael Schäfers, Dario Neri, Samuele Cazzamalli, Philipp Backhaus
Journal of Nuclear Medicine Dec 2023, 64 (12) 1934-1940; DOI: 10.2967/jnumed.123.266007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
Andrea Galbiati, Paulina Dorten, Ettore Gilardoni, Florian Gierse, Matilde Bocci, Aureliano Zana, Jacqueline Mock, Michael Claesener, Juela Cufe, Florian Büther, Klaus Schäfers, Sven Hermann, Michael Schäfers, Dario Neri, Samuele Cazzamalli, Philipp Backhaus
Journal of Nuclear Medicine Dec 2023, 64 (12) 1934-1940; DOI: 10.2967/jnumed.123.266007
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors
  • Google Scholar

More in this TOC Section

  • Establishing In Vitro Dosimetric Models and Dose–Effect Relationships for 177Lu-DOTATATE in Neuroendocrine Tumors
  • Designed Ankyrin Repeat Protein–Mediated Peptide Nucleic Acid–Based Pretargeting: A Proof-of-Principle Study
  • [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B
Show more Basic Science Investigation

Similar Articles

Keywords

  • combination therapies
  • fibroblast activation protein
  • immunocytokines
  • radioligand therapeutics
  • tumor targeting
SNMMI

© 2025 SNMMI

Powered by HighWire